Latest news from AKIGAI

AKIGAI founders featured in Mighty Spark Communications Podcast

AKIGAI Welcomes Strategic Investment Partner!

AKIGAI has secured a strategic partnership with investor Brynjar Forbergskog

FDA grants Orphan Designation for the treatment of CRPS with AKI-007

Dramatic, durable and safe pain relief in chronic CRPS patients has lead to this milestone. A phase III trial is the next step.

Orphan Designation

AKIGAI is excited that we were granted an Orphan Designation from the EMA for the treatment of CRPS with our 1st generation EGFR inhibitor tablet.